Newsfeed

This area is a possible form of presentation for the integration of news sources relating to listed companies.
The presentation level is a template based on short news services, where users can get a quick overview of the latest news. The detailed views enable further research if interested.

This newsfeed is a compilation of current news from direct connections of TopTier NewsWire services related to listed companies. This feed is for demonstration purposes only. Sector-specific news, public relations and product information can be accessed via the GICS portals > Sector Intelligence section.

US08659B1026
Reset filter
Do you already know our new terminal view? Click here.
FIGI: BBG00JNGG9Q2
BBNX
Beta Bionics, Inc.
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: - · THEMEFOLIO: $HLTH
NAME
Beta Bionics, Inc.
ISIN
US08659B1026
TICKER
BBNX
MIC
XNAS
REUTERS
BBNX.OQ
BLOOMBERG
BBNX US
Sat, 19.09.2026       Beta Bionics
US08659B1026

NEW ORLEANS, Sept. 18, 2026 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until November 3, 2026 to file lead plaintiff applications in a securities class action lawsuit against Beta Bionics, Inc. ("Beta Bionics" or the "Company") (NasdaqGM: BBNX), if they purchased or otherwise acquired the...
Read more
Beta Bionics
Technical Analysis Termsheets Terminal
Permalink
Sat, 19.09.2026       Beta Bionics
US08659B1026

Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities who purchased or otherwise acquired Beta Bionics, Inc. (NASDAQ: BBNX) common stock between July 30, 2025 and February 24, 2026, inclusive (the "Class Period"). Beta Bionics is a commercial-stage medical device company that o...
Read more
Beta Bionics
Technical Analysis Termsheets Terminal
Permalink
Fri, 18.09.2026       Beta Bionics
US08659B1026

San Francisco, California--(Newsfile Corp. - September 18, 2026) - Beta Bionics, Inc. (NASDAQ: BBNX) faces a securities class action, which seeks to represent investors who purchased or otherwise acquired shares of the company's common stock between July 30, 2025 and February 24, 2026.The lawsuit follows a series of surprise revelations about the F...
Read more
Beta Bionics
Technical Analysis Termsheets Terminal
Permalink
Fri, 18.09.2026       Beta Bionics
US08659B1026

NEW YORK, Sept. 18, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Beta Bionics, Inc. (NASDAQ: BBNX) between July 30, 2025 and February 24, 2026, both dates inclusive (the "Class Period"), of the important November 3...
Read more
Beta Bionics
Technical Analysis Termsheets Terminal
Permalink
Fri, 18.09.2026       Beta Bionics
US08659B1026

New York, New York--(Newsfile Corp. - September 18, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Beta Bionics, Inc. ("Beta Bionics" or the "Company") (NASDAQ: BBNX) on behalf of investors that purchased or otherwise acquired Beta Bionics common stock between July 30, 2025 and February 24, 2026...
Read more
Beta Bionics
Technical Analysis Termsheets Terminal
Permalink
Fri, 18.09.2026       Beta Bionics
US08659B1026

Boston, Massachusetts--(Newsfile Corp. - September 18, 2026) - Block & Leviton announces that a securities fraud lawsuit has been filed against Beta Bionics, Inc. (NASDAQ: BBNX) and certain of its executives. Investors who have lost money in their Beta Bionics, Inc. investment should contact the firm to learn more about how they might recover t...
Read more
Beta Bionics
Technical Analysis Termsheets Terminal
Permalink
Fri, 18.09.2026       Beta Bionics
US08659B1026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Beta Bionics To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Beta Bionics between July 30, 2025 and February 24, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi...
Read more
Beta Bionics
Technical Analysis Termsheets Terminal
Permalink
Fri, 18.09.2026       Beta Bionics
US08659B1026

SAN FRANCISCO, Sept. 17, 2026 /PRNewswire/ -- Beta Bionics, Inc. (NASDAQ: BBNX) faces a securities class action, which seeks to represent investors who purchased or otherwise acquired shares of the company's common stock between July 30, 2025 and February 24, 2026. The lawsuit follow...
Read more
Beta Bionics
Technical Analysis Termsheets Terminal
Permalink
Thu, 17.09.2026       Beta Bionics
US08659B1026

New York, New York--(Newsfile Corp. - September 17, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Beta Bionics, Inc. ("Beta Bionics" or the "Company") (NASDAQ: BBNX) on behalf of investors that purchased or otherwise acquired Beta Bionics common stock between July 30, 2025 and February 24, 2026...
Read more
Beta Bionics
Technical Analysis Termsheets Terminal
Permalink
Thu, 17.09.2026       Beta Bionics
US08659B1026

IRVINE, Calif., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX) today announced the closing of its previously announced underwritten public offering of 7,652,175 shares of its common stock at a price to the public of $17.25 per share and, in lieu of shares of common stock to certain investors, pre-funded warrants to purchase...
Read more
Beta Bionics
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Thu, 17.09.2026       Beta Bionics
US08659B1026

Time-sensitive notice: the lawsuit asserts that Beta Bionics management described an FDA Form 483 and a subsequent FDA Warning Letter as a "very benign" difference in interpretation of reporting rules, when the agency had allegedly identified systemic quality-management and patient-safety non-conformities.NEW YORK, Sept. 17, 2026 /PRNewswire/ -- S...
Read more
Beta Bionics
Technical Analysis Termsheets Terminal
Permalink
Thu, 17.09.2026       Beta Bionics
US08659B1026

NEW YORK, Sept. 17, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Beta Bionics, Inc. ("Beta Bionics" or the "Company") (NASDAQ: BBNX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail...
Read more
Beta Bionics
Technical Analysis Termsheets Terminal
Permalink
Thu, 17.09.2026       Beta Bionics
US08659B1026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses in Beta Bionics to Contact Him Directly to Discuss Their OptionsNew York, New York--(Newsfile Corp. - September 17, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors of the November 3, 20...
Read more
Beta Bionics
Technical Analysis Termsheets Terminal
Permalink
Wed, 16.09.2026       Beta Bionics
US08659B1026

New York, New York--(Newsfile Corp. - September 16, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Beta Bionics, Inc. ("Beta Bionics" or the "Company") (NASDAQ: BBNX) on behalf of investors that purchased or otherwise acquired Beta Bionics common stock between July 30, 2025 and February 24, 2026...
Read more
Beta Bionics
Technical Analysis Termsheets Terminal
Permalink
Wed, 16.09.2026       Beta Bionics
US08659B1026

Institutional and fiduciary holders of Beta Bionics stock absorbed a decline of roughly $23.09 per share, as a securities class action alleges the Company concealed a June 2025 FDA Form 483 and more than 18,000 unreported iLet customer complaints.NEW YORK, Sept. 16, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies institutional investors in...
Read more
Beta Bionics
Technical Analysis Termsheets Terminal
Permalink
Wed, 16.09.2026       Beta Bionics
US08659B1026

IRVINE, Calif., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX) today announced the pricing of an underwritten public offering of 7,652,175 shares of its common stock at a price to the public of $17.25 per share and, in lieu of shares of common stock to certain investors, pre-funded warrants to purchase 1,043,484 shares of co...
Read more
Beta Bionics
Technical Analysis Termsheets Terminal
Permalink
Tue, 15.09.2026       Beta Bionics
US08659B1026

IRVINE, Calif., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX) today announced that it intends to offer and sell, in an underwritten public offering and subject to market and other conditions, $125.0 million of shares of its common stock. All of the shares are being offered by Beta Bionics. In addition, Beta Bionics intends...
Read more
Beta Bionics
Technical Analysis Termsheets Terminal
Permalink
Tue, 15.09.2026       Beta Bionics
US08659B1026

BENSALEM, Pa., Sept. 15, 2026 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Beta Bionics, Inc. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN BETA BIONICS, INC. (BBNX), CONTACT THE LAW OFFICES OF HOWARD G. SMITH BEFORE NO...
Read more
Beta Bionics
Technical Analysis Termsheets Terminal
Permalink
Tue, 15.09.2026       Beta Bionics
US08659B1026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Beta Bionics To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Beta Bionics between July 30, 2025 and February 24, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi...
Read more
Beta Bionics
Technical Analysis Termsheets Terminal
Permalink
Tue, 15.09.2026       Beta Bionics
US08659B1026

PHILADELPHIA, Sept. 15, 2026 /PRNewswire/ -- Berger Montague PC, a leading national plaintiffs' law firm, announces a class action lawsuit against Beta Bionics, Inc. (NASDAQ: BBNX) ("Beta Bionics" or the "Company") on behalf of investors who purchased or acquired Beta Bionics securities during the period from July 30, 2025 through February 24, 202...
Read more
Beta Bionics
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Tue, 15.09.2026       Beta Bionics
US08659B1026

SAN FRANCISCO, Sept. 15, 2026 /PRNewswire/ -- Beta Bionics, Inc. (NASDAQ: BBNX) faces a securities class action, which seeks to represent investors who purchased or otherwise acquired shares of the company's common stock between July 30, 2025 and February 24, 2026. The lawsuit follow...
Read more
Beta Bionics
Technical Analysis Termsheets Terminal
Permalink
Tue, 15.09.2026       Beta Bionics
US08659B1026

A securities fraud class action lawsuit has been filed on behalf of Beta Bionics investors after its stock plummeted over 37% because Beta Bionics allegedly misled investors about the safety, efficacy, and commercial success of its iLet medical device, potentially violating the federal securities laws.NEW YORK, Sept. 15, 2026 /PRNewswire/ -- Leadi...
Read more
Beta Bionics
Technical Analysis Termsheets Terminal
Permalink
Mon, 14.09.2026       Beta Bionics
US08659B1026

LOS ANGELES, Sept. 14, 2026 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to Beta Bionics, Inc. (BBNX) have opportunity to lead the securities fraud class action lawsuit. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN BETA BIONICS, INC....
Read more
Beta Bionics
Technical Analysis Termsheets Terminal
Permalink
Mon, 14.09.2026       Beta Bionics
US08659B1026

SAN FRANCISCO, Sept. 14, 2026 /PRNewswire/ --  Beta Bionics, Inc. (NASDAQ: BBNX) faces a securities class action, which seeks to represent investors who purchased or otherwise acquired shares of the company's common stock between July 30, 2025 and February 24, 2026. The lawsuit foll...
Read more
Beta Bionics
Technical Analysis Termsheets Terminal
Permalink
Mon, 14.09.2026       Beta Bionics
US08659B1026

San Diego, California--(Newsfile Corp. - September 14, 2026) - Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities who purchased or otherwise acquired Beta Bionics, Inc. (NASDAQ: BBNX) common stock between July 30, 2025 and February 24, 2026, inclusive (the "Class Period"). B...
Read more
Beta Bionics
Technical Analysis Termsheets Terminal
Permalink
Mon, 14.09.2026       Beta Bionics
US08659B1026

IRVINE, Calif., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced U.S. Food and Drug Administration (FDA) clearance of Mint, the Company’s patch pump featuring a transformative reusable and disposable architecture that does not re...
Read more
Beta Bionics
Technical Analysis Termsheets Terminal
Permalink
Sun, 13.09.2026       Beta Bionics
US08659B1026

NEW YORK, Sept. 13, 2026 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of Beta Bionics, Inc. (NASDAQ: BBNX) between July 30, 2025 and February 24, 2026, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish t...
Read more
Beta Bionics
Technical Analysis Termsheets Terminal
Permalink
Sun, 13.09.2026       Beta Bionics
US08659B1026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Beta Bionics To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Beta Bionics between July 30, 2025 and February 24, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi...
Read more
Beta Bionics
Technical Analysis Termsheets Terminal
Permalink
Sat, 12.09.2026       Beta Bionics
US08659B1026

NEW YORK and NEW ORLEANS, Sept. 11, 2026 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Beta Bionics, Inc. ("Beta Bionics" or the "Company") (NasdaqGM: BBNX) of a class action securities lawsuit....
Read more
Beta Bionics
Technical Analysis Termsheets Terminal
Permalink
Fri, 11.09.2026       Beta Bionics
US08659B1026

San Francisco, California--(Newsfile Corp. - September 11, 2026) - Beta Bionics, Inc. (NASDAQ: BBNX) faces a securities class action, which seeks to represent investors who purchased or otherwise acquired shares of the company's common stock between July 30, 2025 and February 24, 2026.The lawsuit follows a series of surprise revelations about the F...
Read more
Beta Bionics
Technical Analysis Termsheets Terminal
Permalink
Fri, 11.09.2026       Beta Bionics
US08659B1026

Law Offices of Howard G. Smith reminds investors of the upcoming November 3, 2026 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Beta Bionics, Inc. (“Beta Bionics” or the “Company”) (NASDAQ: BBNX) securities between July 30, 2025 and February 24, 2026, inclusive (the “Class Period”).IF YOU ARE AN INV...
Read more
Beta Bionics
Technical Analysis Termsheets Terminal
Permalink
Fri, 11.09.2026       Beta Bionics
US08659B1026

New York, New York--(Newsfile Corp. - September 11, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Beta Bionics, Inc. (NASDAQ: BBNX) and certain of its officers.This lawsuit seeks to recover damages against Defendants for alleged violatio...
Read more
Beta Bionics
Technical Analysis Termsheets Terminal
Permalink
Fri, 11.09.2026       Beta Bionics
US08659B1026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Beta Bionics To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Beta Bionics between July 30, 2025 and February 24, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi...
Read more
Beta Bionics
Technical Analysis Termsheets Terminal
Permalink
Fri, 11.09.2026       Beta Bionics
US08659B1026

Philadelphia, Pennsylvania--(Newsfile Corp. - September 11, 2026) - Grabar Law Office is investigating claims on behalf of shareholders of Beta Bionics, Inc. (NASDAQ: BBNX).What is This Investigation About? The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.If you purchased Beta...
Read more
Beta Bionics
Technical Analysis Termsheets Terminal
Permalink
Fri, 11.09.2026       Beta Bionics
US08659B1026

Levi & Korsinsky, LLP alerts investors in Beta Bionics, Inc. (NASDAQ: BBNX) that Chief Executive Officer Sean Saint and Chief Financial Officer Stephen Feider are named as individual defendants in a pending securities class action asserting control person and primary liability claims under Sections 10(b) and 20(a) of the Securities Exchange Ac...
Read more
Beta Bionics
Technical Analysis Termsheets Terminal
Permalink
Fri, 11.09.2026       Beta Bionics
US08659B1026

New York, New York--(Newsfile Corp. - September 10, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Beta Bionics, Inc. ("Beta Bionics" or the "Company") (NASDAQ: BBNX) on behalf of investors that purchased or otherwise acquired Beta Bionics common stock between July 30, 2025 and February 24, 2026...
Read more
Beta Bionics
Technical Analysis Termsheets Terminal
Permalink
Thu, 10.09.2026       Beta Bionics
US08659B1026

The Law Offices of Frank R. Cruz reminds investors of the upcoming November 3, 2026 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors who acquired Beta Bionics, Inc. (“Beta Bionics” or the “Company”) (NASDAQ: BBNX) securities between July 30, 2025 and February 24, 2026, inclusive (...
Read more
Beta Bionics
Technical Analysis Termsheets Terminal
Permalink
Thu, 10.09.2026       Beta Bionics
US08659B1026

NEW YORK, Sept. 10, 2026 /PRNewswire/ -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Beta Bionics, Inc. (NASDAQ: BBNX) and certain of its officers. This lawsuit seeks to recover...
Read more
Beta Bionics
Technical Analysis Termsheets Terminal
Permalink
Thu, 10.09.2026       Beta Bionics
US08659B1026

New York, New York--(Newsfile Corp. - September 10, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Beta Bionics, Inc. (NASDAQ: BBNX) and certain of its officers.This lawsuit seeks to recover damages against Defendants for alleged violatio...
Read more
Beta Bionics
Technical Analysis Termsheets Terminal
Permalink
Thu, 10.09.2026       Beta Bionics
US08659B1026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses in Beta Bionics to Contact Him Directly to Discuss Their OptionsNew York, New York--(Newsfile Corp. - September 10, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors of the November 3, 20...
Read more
Beta Bionics
Technical Analysis Termsheets Terminal
Permalink
Thu, 10.09.2026       Beta Bionics
US08659B1026

Disclosure under scrutiny: the lawsuit contends Beta Bionics' SEC filings described the FDA's Warning Letter as flagging "non-conformities" in its Quality Management System while allegedly omitting that hundreds of unreported iLet complaints involved life-threatening hypoglycemia.NEW YORK, Sept. 10, 2026 /PRNewswire/ -- SueWallSt notifies investor...
Read more
Beta Bionics
Technical Analysis Termsheets Terminal
Permalink
Thu, 10.09.2026       Beta Bionics
US08659B1026

New York, New York--(Newsfile Corp. - September 9, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Beta Bionics, Inc. ("Beta Bionics" or the "Company") (NASDAQ: BBNX) on behalf of investors that purchased or otherwise acquired Beta Bionics common stock between July 30, 2025 and February 24, 2026...
Read more
Beta Bionics
Technical Analysis Termsheets Terminal
Permalink
Wed, 09.09.2026       Beta Bionics
US08659B1026

Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Beta Bionics, Inc. (NASDAQ:BBNX) and certain of the company’s senior executives for securities fraud after its significant stock drop resulting from potential violations of the federal securities laws. If you invested in Beta B...
Read more
Beta Bionics
Technical Analysis Termsheets Terminal
Permalink
Wed, 09.09.2026       Beta Bionics
US08659B1026

The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of shareholders who purchased or otherwise acquired Beta Bionics, Inc. (“Beta Bionics” or the “Company”) (NASDAQ: BBNX) common stock between July 30, 2025 and February 24, 2026, inclusive (the “Class Period”). Beta Bionics, Inc. investors have until Nov...
Read more
Beta Bionics
Technical Analysis Termsheets Terminal
Permalink
Wed, 09.09.2026       Beta Bionics
US08659B1026

New York, New York--(Newsfile Corp. - September 9, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Beta Bionics, Inc. (NASDAQ: BBNX) and certain of its officers.This lawsuit seeks to recover damages against Defendants for alleged violation...
Read more
Beta Bionics
Technical Analysis Termsheets Terminal
Permalink
Wed, 09.09.2026       Beta Bionics
US08659B1026

Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Beta Bionics, Inc. (“Beta Bionics” or the “Company”) (NASDAQ: BBNX) securities between July 30, 2025 and February 24, 2026, inclusive...
Read more
Beta Bionics
Technical Analysis Termsheets Terminal
Permalink
Wed, 09.09.2026       Beta Bionics
US08659B1026

Wall Street stayed constructive on BBNX even after the FDA Warning Letter surfaced, with Leerink writing on January 30, 2026 that management "highlighted there have been no new issues" and Truist stating on February 17, 2026 that the letter was "not on the safety or performance of the company's insulin pump itself." A securities class action alleg...
Read more
Beta Bionics
Technical Analysis Termsheets Terminal
Permalink
Wed, 09.09.2026       Beta Bionics
US08659B1026

Philadelphia, Pennsylvania--(Newsfile Corp. - September 9, 2026) - Berger Montague PC, a leading national plaintiffs' law firm, announces a class action lawsuit against Beta Bionics, Inc. (NASDAQ: BBNX) ("Beta Bionics" or the "Company") on behalf of investors who purchased or acquired Beta Bionics securities during the period from July 30, 2025 thr...
Read more
Beta Bionics
Technical Analysis Termsheets Terminal
Permalink
Wed, 09.09.2026       Beta Bionics
US08659B1026

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Beta Bionics, Inc. (“Beta Bionics” or the “Company”) (NASDAQ: BBNX) common stock between July 30, 2025 and February 24, 2026, inclusive (the “Class Period”). Beta Bionics, Inc. investors have until November 3, 2026 to file a lea...
Read more
Beta Bionics
Technical Analysis Termsheets Terminal
Permalink
Wed, 09.09.2026       Beta Bionics
US08659B1026

The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired Beta Bionics, Inc. (“Beta Bionics” or the “Company”) (NASDAQ: BBNX) securities during the period of July 30, 2025 through February 24, 2026, inclusive (“the Class Period”). Investors are encouraged to contact Lauren Molinaro...
Read more
Beta Bionics
Technical Analysis Termsheets Terminal
Permalink